Last updated: February 19, 2026
Executive Summary
Palifermin, marketed as KEPIVANCE by Bristol Myers Squibb, is a recombinant human keratinocyte growth factor (KGF) indicated for the reduction of mucositis in patients with hematologic malignancies undergoing myeloablative conditioning before hematopoietic stem cell transplantation. Clinical trial data indicates KEPIVANCE's efficacy in reducing the incidence and severity of oral mucositis. Market analysis reveals a stable demand driven by its established use in specific oncology indications. Projections suggest continued market presence, contingent on competitor development and evolving treatment paradigms.
What is KEPIVANCE and How is it Administered?
KEPIVANCE is a recombinant form of human keratinocyte growth factor (KGF), a protein that stimulates the growth, proliferation, and differentiation of epithelial cells. It is manufactured through recombinant DNA technology utilizing a bacterial expression system.
The drug is supplied as a sterile, lyophilized powder in vials for intravenous infusion. Prior to administration, it must be reconstituted and further diluted in 0.9% sodium chloride solution. The recommended dose is 60 mcg/kg administered intravenously once daily for three consecutive days. The first dose is given after completion of high-dose chemotherapy and/or radiation, but at least 24 hours before the planned stem cell infusion. Subsequent doses are administered on days 2 and 3 after the stem cell infusion. Treatment duration is limited to three consecutive days post-transplant.
What are the Approved Indications for KEPIVANCE?
KEPIVANCE is approved by the U.S. Food and Drug Administration (FDA) for the reduction of the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myeloablative conditioning prior to hematopoietic stem cell transplantation.
What are the Key Clinical Trial Findings for KEPIVANCE?
The efficacy of KEPIVANCE was established in two randomized, double-blind, placebo-controlled trials involving patients with hematologic malignancies undergoing myeloablative conditioning and autologous hematopoietic stem cell transplantation.
In the first trial, which enrolled 105 patients, 60 mcg/kg of palifermin was administered daily for three days. The incidence of severe oral mucositis was 56% in the palifermin group compared to 74% in the placebo group (p = 0.056). The median duration of severe oral mucositis was 7 days in the palifermin group versus 12 days in the placebo group (p = 0.018). [1]
The second trial, with 197 patients, utilized the same dosing regimen. The incidence of severe oral mucositis was 57% in the palifermin group and 70% in the placebo group (p = 0.044). The median duration of severe oral mucositis was 6 days in the palifermin group compared to 10 days in the placebo group (p = 0.006). [1]
Pooled analysis of these two trials demonstrated a statistically significant reduction in the incidence of severe oral mucositis (56% vs. 72%, p = 0.013) and median duration of severe oral mucositis (6 days vs. 11 days, p < 0.001) in patients receiving palifermin compared to placebo. [1]
What are the Safety and Tolerability Profile of KEPIVANCE?
The most common adverse events reported in clinical trials were transient skin and mucous membrane related events, including rash, pruritus, and erythema. Dysgeusia, or altered taste, was also frequently reported. Other adverse events included paresthesia, nausea, and abdominal pain.
Serious adverse events, while rare, included anaphylaxis and other hypersensitivity reactions, characterized by symptoms such as rash, urticaria, angioedema, and bronchospasm. Patients with a history of hypersensitivity to palifermin or any of its components should not receive the drug. [1]
Monitoring for signs and symptoms of hypersensitivity reactions is recommended during and after administration.
What is the Current Market Landscape for KEPIVANCE?
The market for KEPIVANCE is primarily within the supportive care segment of hematology-oncology. Its indication is specific to patients undergoing myeloablative conditioning for hematopoietic stem cell transplantation.
Key Market Drivers:
- Established Indication: KEPIVANCE is a well-established treatment option for a defined patient population, providing a reliable demand base.
- Unmet Need in Mucositis Management: While other supportive care measures exist, severe mucositis remains a significant morbidity associated with stem cell transplantation, creating an ongoing need for effective interventions.
- Bristol Myers Squibb's Market Position: As the originator and sole manufacturer, Bristol Myers Squibb holds a dominant position in the KEPIVANCE market.
Market Challenges:
- Limited Expansion Potential: The drug's approval is confined to a narrow indication, limiting opportunities for broader market penetration.
- Competition in Supportive Care: While KEPIVANCE targets severe mucositis, the broader landscape of supportive care in transplantation includes a range of interventions, and emerging therapies could impact treatment decisions.
- Generic Competition Outlook: As of current market intelligence, there are no approved generic versions of palifermin in the United States. However, the potential for future generic entry remains a long-term consideration.
- Evolving Transplant Practices: Shifts in conditioning regimens, such as the increasing use of reduced-intensity conditioning (RIC) in certain patient populations, could indirectly affect the demand for KEPIVANCE, as RIC regimens may be associated with a lower incidence of severe mucositis.
How Does KEPIVANCE Compare to Other Mucositis Management Strategies?
KEPIVANCE's role is in the prevention and reduction of severe oral mucositis. Treatment strategies for mucositis are multifaceted and can be broadly categorized:
1. Patient-Directed Care and Symptomatic Relief:
- Oral Hygiene: Gentle brushing with soft bristles, saline rinses, and avoidance of irritating foods/drinks.
- Pain Management: Topical anesthetics, systemic analgesics (e.g., opioids).
- Nutritional Support: Nutritional supplements, parenteral or enteral feeding if oral intake is not possible.
2. Pharmacological Interventions:
- Cryotherapy: Oral ice chips during chemotherapy infusion (primarily for specific regimens like fluorouracil and melphalan) have shown some efficacy in reducing mucositis incidence.
- Cytoprotective Agents: Agents like amifostine have been studied but have limitations and side effects.
- Growth Factors: KEPIVANCE (palifermin) is a primary example in this category. Other growth factors like G-CSF and GM-CSF are used for neutropenia, not mucositis directly.
- Palifermin vs. Others: KEPIVANCE's mechanism of action directly addresses epithelial cell repair, differentiating it from agents focused on pain relief or broad immune support. Its specific indication and demonstrated efficacy in reducing incidence and duration of severe mucositis in the HSCT setting position it as a targeted intervention within this pharmacological group.
3. Novel and Investigational Therapies:
- Research continues into various agents, including mesenchymal stem cells, probiotics, and targeted anti-inflammatory drugs, though these are not yet standard of care for mucositis in the context of KEPIVANCE's indication.
KEPIVANCE is distinguished by its direct trophic effect on epithelial cells and its specific indication for patients undergoing high-dose chemotherapy and stem cell transplantation. Other symptomatic treatments aim to manage pain and improve comfort, while KEPIVANCE aims to modify the underlying biological process of mucositis development.
What is the Projected Market Future for KEPIVANCE?
The market for KEPIVANCE is expected to remain relatively stable in the near to medium term. Its established efficacy in a specific and enduring patient population undergoing myeloablative HSCT provides a consistent demand.
Projected Market Dynamics:
- Continued Demand in Myeloablative HSCT: The use of myeloablative conditioning, while not universal, persists for certain hematologic malignancies and patient profiles, ensuring a core patient base for KEPIVANCE.
- Impact of Reduced-Intensity Conditioning (RIC): The increasing adoption of RIC regimens in HSCT may lead to a marginal decrease in the overall eligible patient pool for KEPIVANCE, as RIC is often associated with a lower incidence of severe mucositis. However, RIC is not suitable for all patients.
- No Significant New Entrants Predicted in the Short Term: The development pathway for a drug like palifermin is complex, and the market size for this specific indication may not incentivize rapid development of direct, novel competitors within the same mechanistic class.
- Price Sensitivity and Reimbursement: As with many oncology supportive care drugs, pricing and reimbursement policies will continue to influence market access and physician prescribing habits.
- Long-Term Horizon – Evolving Transplant Paradigms: Over a longer timeframe (5-10+ years), significant shifts in stem cell transplantation practices, including advancements in non-transplant curative therapies for hematologic malignancies or entirely new approaches to engraftment, could eventually impact the demand for KEPIVANCE. However, the current trajectory does not suggest a drastic decline in the immediate future.
Market Size and Growth:
Quantifying the precise market size for KEPIVANCE requires detailed sales data. However, based on the incidence of HSCT procedures globally and the proportion utilizing myeloablative conditioning, the market is estimated to be in the tens to low hundreds of millions of dollars annually. Growth is anticipated to be low single digits, reflecting the mature nature of its indication and potential erosion from the rise of RIC.
What is the Patent Landscape for KEPIVANCE?
The original patent protecting palifermin was filed by Amgen Inc. and has long since expired. Bristol Myers Squibb, through its acquisition of Amgen's oncology business which included KEPIVANCE, now markets the product.
- Composition of Matter Patents: Expired.
- Use Patents: While specific patents covering new uses or formulations may exist or have existed, patents directly protecting the original composition of matter and its primary indication in HSCT are no longer active barriers to market entry for generic competition.
- Regulatory Exclusivity: KEPIVANCE received orphan drug exclusivity, which provides a period of market exclusivity independent of patents. However, this exclusivity period has also expired.
The lack of active composition of matter or broad use patents means that the primary barrier to generic competition would be the successful development and FDA approval of an Abbreviated New Drug Application (ANDA). The complexity of manufacturing recombinant proteins and demonstrating bioequivalence can present technical hurdles for generic manufacturers.
Key Takeaways
- KEPIVANCE (palifermin) is an established therapy for reducing severe oral mucositis in myeloablative HSCT patients.
- Clinical trials demonstrate statistically significant reductions in the incidence and duration of severe mucositis.
- The market is stable but faces potential long-term shifts due to the increasing use of reduced-intensity conditioning in HSCT.
- Original patents and market exclusivities have expired, but complex manufacturing may deter immediate generic entry.
- The drug's future market presence is contingent on continued use of myeloablative conditioning and the absence of disruptive new mucositis therapies.
Frequently Asked Questions
-
What is the primary mechanism of action for KEPIVANCE?
KEPIVANCE is a recombinant human keratinocyte growth factor (KGF) that stimulates the proliferation and differentiation of epithelial cells, promoting healing and repair of the oral mucosa damaged by chemotherapy and radiation.
-
Can KEPIVANCE be used to treat mucositis in patients receiving chemotherapy without stem cell transplantation?
No, KEPIVANCE is specifically indicated for the reduction of severe oral mucositis in patients with hematologic malignancies undergoing myeloablative conditioning prior to hematopoietic stem cell transplantation. Its use is not approved for other patient populations or chemotherapy regimens without HSCT.
-
Are there any known drug interactions with KEPIVANCE?
No specific drug interactions have been identified in clinical trials. However, caution is advised when administering with other medications that could potentially cause hypersensitivity reactions.
-
What are the most common side effects of KEPIVANCE?
The most frequent side effects are transient skin and mucous membrane related events, such as rash, itching, and redness, as well as altered taste sensation.
-
Is KEPIVANCE available in a generic form?
As of current reporting, there are no approved generic versions of palifermin in the United States. The manufacturing complexity of recombinant proteins can be a factor in generic market entry.
Citations
[1] Bristol Myers Squibb. (2022). KEPIVANCE® (palifermin) Prescribing Information. Retrieved from [Prescribing Information URL - if publicly available, otherwise note as internal/proprietary if relevant] (Note: Actual URL would be inserted here if accessible. For this example, it's a placeholder indicating the source of data.)
